LATE-NC staging in routine neuropathologic diagnosis: an update
Open accessThe DOI matches its Crossref record; 156 of the 156 references it cites were found in a registry or an index.
Abstract
An international consensus report in 2019 recommended a classification system for limbic-predominant age-related TDP-43 encephalopathy neuropathologic changes (LATE-NC). The suggested neuropathologic staging system and nomenclature have proven useful for autopsy practice and dementia research. However, some issues remain unresolved, such as cases with unusual features that do not fit with current diagnostic categories. The goal of this report is to update the neuropathologic criteria for the diagnosis and staging of LATE-NC, based primarily on published data. We provide practical suggestions about how to integrate available genetic information and comorbid pathologies [e.g., Alzheimer’s disease neuropathologic changes (ADNC) and Lewy body disease]. We also describe recent research findings that have enabled more precise guidance on how to differentiate LATE-NC from other subtypes of TDP-43 pathology [e.g., frontotemporal lobar degeneration (FTLD) and amyotrophic lateral sclerosis (ALS)], and how to render diagnoses in unusual situations in which TDP-43 pathology does not follow the staging scheme proposed in 2019. Specific recommendations are also made on when not to apply this diagnostic term based on current knowledge. Neuroanatomical regions of interest in LATE-NC are described in detail and the implications for TDP-43 immunohistochemical results are specified more precisely. We also highlight questions that remain unresolved and areas needing additional study. In summary, the current work lays out a number of recommendations to improve the precision of LATE-NC staging based on published reports and diagnostic experience.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Amyloid oligomers exacerbate tau pathology in a mouse model of tauopathy
Selenica, M.-L. B., Brownlow, M., Jimenez, J. P., Lee, D. C., Pena, G., Dickey, C. A., Gordon, M. N., & Morgan, D. (2013) · Neurodegenerative Diseases · doi:10.1159/000337230 · Cited by 10,359
Ubiquitinated TDP-43 in Frontotemporal Lobar Degeneration and Amyotrophic Lateral Sclerosis
Neumann, M., Sampathu, D. M., Kwong, L. K., Truax, A. C., Micsenyi, M. C., Chou, T. T., Bruce, J., Schuck, T., Grossman, M., Clark, C. M., et al. (2006) · Science · doi:10.1126/science.1134108 · Cited by 6,576 · cited 2×
“The defining feature of FTLD-TDP is the presence of NCIs and dystrophic TDP-43 immunoreactive processes in affected frontotemporal cortices [23, 93, 94, 122].”
Self-citationPhases of Aβ-deposition in the human brain and its relevance for the development of AD
Thal, D. R., Rüb, U., Orantes, M., & Braak, H. (2002) · Neurology · doi:10.1212/wnl.58.12.1791 · Cited by 3,490 · cited 1×
“LATE-NC staging, like other neurodegenerative disease staging systems [12, 18–20, 140], is based on anatomical”
Self-citationStages in the development of Parkinson’s disease-related pathology
Braak, H., Ghebremedhin, E., Rüb, U., Bratzke, H., & Del Tredici, K. (2004) · Cell and Tissue Research · doi:10.1007/s00441-004-0956-9 · Cited by 2,689 · cited 1×
“LATE-NC staging, like other neurodegenerative disease staging systems [12, 18–20, 140], is based on anatomical”
Stages of the Pathologic Process in Alzheimer Disease: Age Categories From 1 to 100 Years
Braak, H., Thal, D. R., Ghebremedhin, E., & Del Tredici, K. (2011) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318232a379 · Cited by 2,194
Self-citationNelson, P. T., Alafuzoff, I., Bigio, E. H., Bouras, C., Braak, H., Cairns, N. J., Castellani, R. J., Crain, B. J., Davies, P., Tredici, K. D., et al. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31825018f7 · Cited by 2,050 · cited 1×
“Similar to other age-related neurodegenerative disease processes, it is not possible to confidently predict clinical implications of LATE-NC in a given individual, especially if there are multiple concurrent pathologies [24, 98, 108, 109, 112, 143, 146].”
Self-citationLimbic-predominant age-related TDP-43 encephalopathy (LATE): consensus working group report
Nelson, P. T., Dickson, D. W., Trojanowski, J. Q., Jack, C. R., Boyle, P. A., Arfanakis, K., Rademakers, R., Alafuzoff, I., Attems, J., Brayne, C., et al. (2019) · Brain · doi:10.1093/brain/awz099 · Cited by 1,547 · cited 7×
“Based on current knowledge, our recommendations are as follows: • TDP-43 pathology in LATE-NC has histomorphologic features that may be similar to FTLD-TDP type A or less commonly type B [8, 114, 131, 149].”
InfluentialSelf-citationCairns, N. J., Bigio, E. H., Mackenzie, I. R. A., Neumann, M., Lee, V. M.-Y., Hatanpaa, K. J., White, C. L., Schneider, J. A., Grinberg, L. T., Halliday, G., et al. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0237-2 · Cited by 1,110 · cited 1×
“The defining feature of FTLD-TDP is the presence of NCIs and dystrophic TDP-43 immunoreactive processes in affected frontotemporal cortices [23, 93, 94, 122].”
Self-citationStages of pTDP‐43 pathology in amyotrophic lateral sclerosis
Brettschneider, J., Del Tredici, K., Toledo, J. B., Robinson, J. L., Irwin, D. J., Grossman, M., Suh, E., Van Deerlin, V. M., Wood, E. M., Baek, Y., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23937 · Cited by 1,065 · cited 3×
“Yet, the TDP-43 neuro-pathologic changes in ALS differ from LATE-NC: motor neuron TDP-43 pathology has not been reported in LATE-NC, but is an early site of TDP-43 pathology in ALS [20], and is even seen in some FTLD-TDP cases without clinical ALS [32].”
Self-citationA harmonized classification system for FTLD-TDP pathology
Mackenzie, I. R. A., Neumann, M., Baborie, A., Sampathu, D. M., Du Plessis, D., Jaros, E., Perry, R. H., Trojanowski, J. Q., Mann, D. M. A., & Lee, V. M. Y. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0845-8 · Cited by 1,017 · cited 1×
“…of TDP-43 pathology in the cerebral neocortex allow for recognition of at least five subtypes of FTLD-TDP, each with relatively specific clinical and genetic correlations and increasingly recognized molecular differences in the nature of the TDP-43 aggregates [84, 90, 92, 119, 121, 124].”
Self-citationMackenzie, I. R. A., Neumann, M., Bigio, E. H., Cairns, N. J., Alafuzoff, I., Kril, J., Kovacs, G. G., Ghetti, B., Halliday, G., Holm, I. E., et al. (2010) · Acta Neuropathologica · doi:10.1007/s00401-009-0612-2 · Cited by 1,012 · cited 1×
“The defining feature of FTLD-TDP is the presence of NCIs and dystrophic TDP-43 immunoreactive processes in affected frontotemporal cortices [23, 93, 94, 122].”
Self-citationTDP‐43 immunoreactivity in hippocampal sclerosis and Alzheimer's disease
Amador‐Ortiz, C., Lin, W., Ahmed, Z., Personett, D., Davies, P., Duara, R., Graff‐Radford, N. R., Hutton, M. L., & Dickson, D. W. (2007) · Annals of Neurology · doi:10.1002/ana.21154 · Cited by 916 · cited 1×
“HS in the elderly is strongly associated with LATE-NC [7], with 75–90% of HS cases in aging being seen in cases with LATE-NC [34, 38, 47, 103, 106, 118].”
Self-citationthe TBI/CTE group, McKee, A. C., Cairns, N. J., Dickson, D. W., Folkerth, R. D., Dirk Keene, C., Litvan, I., Perl, D. P., Stein, T. D., Vonsattel, J.-P., et al. (2016) · Acta Neuropathologica · doi:10.1007/s00401-015-1515-z · Cited by 885 · cited 1×
“For persons with a clinical history of brain trauma—traumatic brain injury (TBI) and/or chronic traumatic encephalopathy (CTE)–TDP-43 pathologic changes may be seen, but not necessarily related to LATE-NC [3, 60, 96, 97, 126].”
Self-citationPhosphorylated TDP‐43 in frontotemporal lobar degeneration and amyotrophic lateral sclerosis
Hasegawa, M., Arai, T., Nonaka, T., Kametani, F., Yoshida, M., Hashizume, Y., Beach, T. G., Buratti, E., Baralle, F., Morita, M., et al. (2008) · Annals of Neurology · doi:10.1002/ana.21425 · Cited by 777 · cited 1×
“…TDP-43 immunoreactive neuronal cytoplasmic inclusions; NFT: neurofibrillary tangles; TErC: transen-torhinal cortex; Unc: uncus ◂ most commonly used [44, 120], robustly label pathologic TDP-43 inclusions and do not stain normal (nonphosphorylated) nuclear TDP-43 protein, thereby facilitating…”
Self-citationBarker, W. W., Luis, C. A., Kashuba, A., Luis, M., Harwood, D. G., Loewenstein, D., Waters, C., Jimison, P., Shepherd, E., Sevush, S., et al. (2002) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-200210000-00001 · Cited by 705 · cited 1×
“For persons with a clinical history of brain trauma—traumatic brain injury (TBI) and/or chronic traumatic encephalopathy (CTE)–TDP-43 pathologic changes may be seen, but not necessarily related to LATE-NC [3, 60, 96, 97, 126].”
Self-citationTDP-43 proteinopathy and motor neuron disease in chronic traumatic encephalopathy
McKee, A. C., Gavett, B. E., Stern, R. A., Nowinski, C. J., Cantu, R. C., Kowall, N. W., Perl, D. P., Hedley-Whyte, E. T., Price, B., Sullivan, C., et al. (2010) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e3181ee7d85 · Cited by 659 · cited 1×
“For persons with a clinical history of brain trauma—traumatic brain injury (TBI) and/or chronic traumatic encephalopathy (CTE)–TDP-43 pathologic changes may be seen, but not necessarily related to LATE-NC [3, 60, 96, 97, 126].”
Neumann, M., Kwong, L. K., Lee, E. B., Kremmer, E., Flatley, A., Xu, Y., Forman, M. S., Troost, D., Kretzschmar, H. A., Trojanowski, J. Q., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-008-0477-9 · Cited by 604 · cited 1×
“…immunoreactive neuronal cytoplasmic inclusions; NFT: neurofibrillary tangles; TErC: transen-torhinal cortex; Unc: uncus ◂ most commonly used [44, 120], robustly label pathologic TDP-43 inclusions and do not stain normal (nonphosphorylated) nuclear TDP-43 protein, thereby facilitating…”
Self-citationTDP-43 is a key player in the clinical features associated with Alzheimer’s disease
Josephs, K. A., Whitwell, J. L., Weigand, S. D., Murray, M. E., Tosakulwong, N., Liesinger, A. M., Petrucelli, L., Senjem, M. L., Knopman, D. S., Boeve, B. F., et al. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1269-z · Cited by 481 · cited 1×
“Clinical–pathological studies demonstrated that LATE-NC is associated with cognitive impairment (often with amnestic features), independent of other disease processes [17, 36, 42, 51, 58, 62, 68, 72, 88, 103, 104, 111, 130, 132, 135].”
Self-citationErkrankung des Ammonshorns als aetiologisches Moment der Epilepsie
Sommer, W. (1880) · Archiv für Psychiatrie und Nervenkrankheiten · doi:10.1007/bf02224538 · Cited by 459
Higashi, S., Iseki, E., Yamamoto, R., Minegishi, M., Hino, H., Fujisawa, K., Togo, T., Katsuse, O., Uchikado, H., Furukawa, Y., et al. (2007) · Brain Research · doi:10.1016/j.brainres.2007.09.048 · Cited by 419
Mackenzie, I. R. A., Neumann, M., Bigio, E. H., Cairns, N. J., Alafuzoff, I., Kril, J., Kovacs, G. G., Ghetti, B., Halliday, G., Holm, I. E., et al. (2009) · Acta Neuropathologica · doi:10.1007/s00401-008-0460-5 · Cited by 418 · cited 1×
“The defining feature of FTLD-TDP is the presence of NCIs and dystrophic TDP-43 immunoreactive processes in affected frontotemporal cortices [23, 93, 94, 122].”
Self-citationTDP-43 stage, mixed pathologies, and clinical Alzheimer’s-type dementia
James, B. D., Wilson, R. S., Boyle, P. A., Trojanowski, J. Q., Bennett, D. A., & Schneider, J. A. (2016) · Brain · doi:10.1093/brain/aww224 · Cited by 407 · cited 1×
“Clinical–pathological studies demonstrated that LATE-NC is associated with cognitive impairment (often with amnestic features), independent of other disease processes [17, 36, 42, 51, 58, 62, 68, 72, 88, 103, 104, 111, 130, 132, 135].”
Self-citationUryu, K., Nakashima-Yasuda, H., Forman, M. S., Kwong, L. K., Clark, C. M., Grossman, M., Miller, B. L., Kretzschmar, H. A., Lee, V. M.-Y., Trojanowski, J. Q., et al. (2008) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e31817713b5 · Cited by 382 · cited 2×
“Age-related TDP-43 pathology and associated clinical features have been described by many investigators over past decades [6, 14, 28, 30, 31, 46, 49, 59, 66, 70, 72, 85, 103, 106, 117, 125, 137, 145, 146, 148, 155, 158, 161], but a consensus nomenclature was lacking until recently.”
Self-citationUpdated TDP-43 in Alzheimer’s disease staging scheme
Josephs, K. A., Murray, M. E., Whitwell, J. L., Tosakulwong, N., Weigand, S. D., Petrucelli, L., Liesinger, A. M., Petersen, R. C., Parisi, J. E., & Dickson, D. W. (2016) · Acta Neuropathologica · doi:10.1007/s00401-016-1537-1 · Cited by 372
Self-citationStaging TDP-43 pathology in Alzheimer’s disease
Josephs, K. A., Murray, M. E., Whitwell, J. L., Parisi, J. E., Petrucelli, L., Jack, C. R., Petersen, R. C., & Dickson, D. W. (2014) · Acta Neuropathologica · doi:10.1007/s00401-013-1211-9 · Cited by 366
Self-citationCerebrovascular Pathology and Dementia in Autopsied Honolulu‐Asia Aging Study Participants
WHITE, L., PETROVITCH, H., HARDMAN, J., NELSON, J., DAVIS, D. G., ROSS, G. W., MASAKI, K., LAUNER, L., & MARKESBERY, W. R. (2002) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2002.tb04794.x · Cited by 357 · cited 1×
“Age-related TDP-43 pathology and associated clinical features have been described by many investigators over past decades [6, 14, 28, 30, 31, 46, 49, 59, 66, 70, 72, 85, 103, 106, 117, 125, 137, 145, 146, 148, 155, 158, 161], but a consensus nomenclature was lacking until recently.”
Phosphorylated TDP-43 in Alzheimer’s disease and dementia with Lewy bodies
Arai, T., Mackenzie, I. R. A., Hasegawa, M., Nonoka, T., Niizato, K., Tsuchiya, K., Iritani, S., Onaya, M., & Akiyama, H. (2009) · Acta Neuropathologica · doi:10.1007/s00401-008-0480-1 · Cited by 345 · cited 1×
“It has been recognized for over a decade that TDP-43 pathology is often comorbid with ADNC, Lewy body pathology, or both [8, 10, 46, 66, 67].”
Self-citationIgaz, L. M., Kwong, L. K., Xu, Y., Truax, A. C., Uryu, K., Neumann, M., Clark, C. M., Elman, L. B., Miller, B. L., Grossman, M., et al. (2008) · The American Journal of Pathology · doi:10.2353/ajpath.2008.080003 · Cited by 327 · cited 2×
“The antibody used for pathologic diagnosis and associated protocols may affect the ability to detect TDP-43 inclusions [40, 53, 79].”
Self-citationAttributable risk of Alzheimer's dementia attributed to age-related neuropathologies
Boyle, P. A., Yu, L., Leurgans, S. E., Wilson, R. S., Brookmeyer, R., Schneider, J. A., & Bennett, D. A. (2019) · Annals of Neurology · doi:10.1002/ana.25380 · Cited by 318 · cited 2×
“Many studies have demonstrated that LATE-NC is associated with additive cognitive impairment for a given amount of other pathologic changes [4, 16, 17, 72, 103, 111, 127].”
Self-citationHippocampal sclerosis and TDP ‐43 pathology in aging and Alzheimer disease
Nag, S., Yu, L., Capuano, A. W., Wilson, R. S., Leurgans, S. E., Bennett, D. A., & Schneider, J. A. (2015) · Annals of Neurology · doi:10.1002/ana.24388 · Cited by 305 · cited 2×
“Age-related TDP-43 pathology and associated clinical features have been described by many investigators over past decades [6, 14, 28, 30, 31, 46, 49, 59, 66, 70, 72, 85, 103, 106, 117, 125, 137, 145, 146, 148, 155, 158, 161], but a consensus nomenclature was lacking until recently.”
Self-citationDickson, D. W., Davies, P., Bevona, C., Van Hoeven, K. H., Factor, S. M., Grober, E., Aronson, M. K., & Crystal, H. A. (1994) · Acta Neuropathologica · doi:10.1007/bf00293396 · Cited by 293 · cited 1×
“Age-related TDP-43 pathology and associated clinical features have been described by many investigators over past decades [6, 14, 28, 30, 31, 46, 49, 59, 66, 70, 72, 85, 103, 106, 117, 125, 137, 145, 146, 148, 155, 158, 161], but a consensus nomenclature was lacking until recently.”
Self-citationAttems, J., Toledo, J. B., Walker, L., Gelpi, E., Gentleman, S., Halliday, G., Hortobagyi, T., Jellinger, K., Kovacs, G. G., Lee, E. B., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-020-02255-2 · Cited by 280 · cited 1×
“LATE-NC staging, like other neurodegenerative disease staging systems [12, 18–20, 140], is based on anatomical”
Self-citationHippocampal sclerosis in advanced age: clinical and pathological features
Nelson, P. T., Schmitt, F. A., Lin, Y., Abner, E. L., Jicha, G. A., Patel, E., Thomason, P. C., Neltner, J. H., Smith, C. D., Santacruz, K. S., et al. (2011) · Brain · doi:10.1093/brain/awr053 · Cited by 279 · cited 1×
“Age-related TDP-43 pathology and associated clinical features have been described by many investigators over past decades [6, 14, 28, 30, 31, 46, 49, 59, 66, 70, 72, 85, 103, 106, 117, 125, 137, 145, 146, 148, 155, 158, 161], but a consensus nomenclature was lacking until recently.”
Self-citationLee, E. B., Porta, S., Michael Baer, G., Xu, Y., Suh, E., Kwong, L. K., Elman, L., Grossman, M., Lee, V. M.-Y., Irwin, D. J., et al. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1679-9 · Cited by 259 · cited 2×
“…of TDP-43 pathology in the cerebral neocortex allow for recognition of at least five subtypes of FTLD-TDP, each with relatively specific clinical and genetic correlations and increasingly recognized molecular differences in the nature of the TDP-43 aggregates [84, 90, 92, 119, 121, 124].”
Self-citationAbnormal TDP-43 immunoreactivity in AD modifies clinicopathologic and radiologic phenotype
Josephs, K. A., Whitwell, J. L., Knopman, D. S., Hu, W. T., Stroh, D. A., Baker, M., Rademakers, R., Boeve, B. F., Parisi, J. E., Smith, G. E., et al. (2008) · Neurology · doi:10.1212/01.wnl.0000304041.09418.b1 · Cited by 253 · cited 2×
“It has been recognized for over a decade that TDP-43 pathology is often comorbid with ADNC, Lewy body pathology, or both [8, 10, 46, 66, 67].”
Self-citationTDP-43 is deposited in the Guam parkinsonism-dementia complex brains
Hasegawa, M., Arai, T., Akiyama, H., Nonaka, T., Mori, H., Hashimoto, T., Yamazaki, M., & Oyanagi, K. (2007) · Brain · doi:10.1093/brain/awm065 · Cited by 242 · cited 1×
“For example, TDP-43 pathology is often seen in corticobasal degeneration, Perry syndrome, Alexander disease, and the Parkinsonism–dementia complex diseases of Guam and Kii [43, 75, 148, 152, 156].”
Self-citationCorrelates of hippocampal neuron number in Alzheimer's disease and ischemic vascular dementia
Zarow, C., Vinters, H. V., Ellis, W. G., Weiner, M. W., Mungas, D., White, L., & Chui, H. C. (2005) · Annals of Neurology · doi:10.1002/ana.20503 · Cited by 241 · cited 1×
“Prior studies of HS-related histomorphology [45, 56, 160], and the recent work by Hokkanen et al. [47], provided methodologies to study HS pathologic features systematically.”
Nelson, P. T., Abner, E. L., Schmitt, F. A., Kryscio, R. J., Jicha, G. A., Smith, C. D., Davis, D. G., Poduska, J. W., Patel, E., Mendiondo, M. S., et al. (2010) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00244.x · Cited by 239 · cited 2×
“Many studies have demonstrated that LATE-NC is associated with additive cognitive impairment for a given amount of other pathologic changes [4, 16, 17, 72, 103, 111, 127].”
Self-citationTo what degree is late life cognitive decline driven by age-related neuropathologies?
Boyle, P. A., Wang, T., Yu, L., Wilson, R. S., Dawe, R., Arfanakis, K., Schneider, J. A., & Bennett, D. A. (2021) · Brain · doi:10.1093/brain/awab092 · Cited by 219 · cited 3×
“For example, in an attributable risk analysis based on all observed pathologic changes that may contribute to cognitive impairment in a large community cohort, LATE-NC accounted for more than 15% of identified amnestic dementia risk [16, 114].”
Self-citationCombined neuropathological pathways account for age‐related risk of dementia
Power, M. C., Mormino, E., Soldan, A., James, B. D., Yu, L., Armstrong, N. M., Bangen, K. J., Delano‐Wood, L., Lamar, M., Lim, Y. Y., et al. (2018) · Annals of Neurology · doi:10.1002/ana.25246 · Cited by 217 · cited 1×
“Many studies have demonstrated that LATE-NC is associated with additive cognitive impairment for a given amount of other pathologic changes [4, 16, 17, 72, 103, 111, 127].”
Self-citationThe neuropathology associated with repeat expansions in the C9ORF72 gene
Mackenzie, I. R. A., Frick, P., & Neumann, M. (2014) · Acta Neuropathologica · doi:10.1007/s00401-013-1232-4 · Cited by 206
Self-citationThe development and convergence of co-pathologies in Alzheimer’s disease
Robinson, J. L., Richardson, H., Xie, S. X., Suh, E., Van Deerlin, V. M., Alfaro, B., Loh, N., Porras-Paniagua, M., Nirschl, J. J., Wolk, D., et al. (2021) · Brain · doi:10.1093/brain/awaa438 · Cited by 203 · cited 2×
“This terminology has been adopted widely [16, 25, 48, 50–52, 57, 74, 81, 95, 100, 132, 135, 138, 153].”
Self-citationBlevins, B. L., Vinters, H. V., Love, S., Wilcock, D. M., Grinberg, L. T., Schneider, J. A., Kalaria, R. N., Katsumata, Y., Gold, B. T., Wang, D. J. J., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-020-02235-6 · Cited by 200 · cited 1×
“Additional pressing research is needed to define and stratify risk factors and interactions with other diseases, including various neurodegenerative and neurovascular disorders (see, for example, Refs [15, 37, 128]).”
Self-citationHippocampal sclerosis of aging, a prevalent and high-morbidity brain disease
Nelson, P. T., Smith, C. D., Abner, E. L., Wilfred, B. J., Wang, W.-X., Neltner, J. H., Baker, M., Fardo, D. W., Kryscio, R. J., Scheff, S. W., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1154-1 · Cited by 197 · cited 4×
“These factors increase the likelihood of poor inter-rater agreement on the neuropathologic diagnosis of HS, and help explain the differing frequencies of HS reported in various autopsy series [34, 38, 73, 86, 88, 102, 118, 144, 159].”
InfluentialSelf-citationNelson, P. T., Brayne, C., Flanagan, M. E., Abner, E. L., Agrawal, S., Attems, J., Castellani, R. J., Corrada, M. M., Cykowski, M. D., Di, J., et al. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02444-1 · Cited by 174 · cited 3×
“Recent literature indicates the scope of the challenge, even for this relatively simple pathologic staging system, as a wide variation of results was reported in the proportion of subjects with LATE-NC Stage 1 in a survey of community-based autopsy cohorts [113].”
Self-citationDavidson, Y. S., Raby, S., Foulds, P. G., Robinson, A., Thompson, J. C., Sikkink, S. K., Yusuf, I. H., Amin, H., DuPlessis, D., Troakes, C., et al. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0879-y · Cited by 168 · cited 1×
“Age-related TDP-43 pathology and associated clinical features have been described by many investigators over past decades [6, 14, 28, 30, 31, 46, 49, 59, 66, 70, 72, 85, 103, 106, 117, 125, 137, 145, 146, 148, 155, 158, 161], but a consensus nomenclature was lacking until recently.”
TDP-43 pathology in anterior temporal pole cortex in aging and Alzheimer’s disease
Nag, S., Yu, L., Boyle, P. A., Leurgans, S. E., Bennett, D. A., & Schneider, J. A. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0531-3 · Cited by 166
Self-citationKoper, M. J., Van Schoor, E., Ospitalieri, S., Vandenberghe, R., Vandenbulcke, M., von Arnim, C. A. F., Tousseyn, T., Balusu, S., De Strooper, B., & Thal, D. R. (2020) · Acta Neuropathologica · doi:10.1007/s00401-019-02103-y · Cited by 166 · cited 1×
“For more data and discussion related to immunostaining of GVD, see Refs [51, 69, 76, 77, 141, 151].”
Self-citationNon-Alzheimer’s contributions to dementia and cognitive resilience in The 90+ Study
Robinson, J. L., Corrada, M. M., Kovacs, G. G., Dominique, M., Caswell, C., Xie, S. X., Lee, V. M.-Y., Kawas, C. H., & Trojanowski, J. Q. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1872-5 · Cited by 162 · cited 1×
“Clinical–pathological studies demonstrated that LATE-NC is associated with cognitive impairment (often with amnestic features), independent of other disease processes [17, 36, 42, 51, 58, 62, 68, 72, 88, 103, 104, 111, 130, 132, 135].”
Self-citationTDP-43 in differential diagnosis of motor neuron disorders
Dickson, D. W., Josephs, K. A., & Amador, C. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0234-5 · Cited by 157 · cited 1×
“Yet, the TDP-43 neuro-pathologic changes in ALS differ from LATE-NC: motor neuron TDP-43 pathology has not been reported in LATE-NC, but is an early site of TDP-43 pathology in ALS [20], and is even seen in some FTLD-TDP cases without clinical ALS [32].”
Self-citationTAR DNA‐binding protein 43 and pathological subtype of Alzheimer's disease impact clinical features
Josephs, K. A., Whitwell, J. L., Tosakulwong, N., Weigand, S. D., Murray, M. E., Liesinger, A. M., Petrucelli, L., Senjem, M. L., Ivnik, R. J., Parisi, J. E., et al. (2015) · Annals of Neurology · doi:10.1002/ana.24493 · Cited by 147 · cited 1×
“It has been recognized for over a decade that TDP-43 pathology is often comorbid with ADNC, Lewy body pathology, or both [8, 10, 46, 66, 67].”
Self-citationDifferential clinicopathologic and genetic features of late-onset amnestic dementias
Murray, M. E., Cannon, A., Graff-Radford, N. R., Liesinger, A. M., Rutherford, N. J., Ross, O. A., Duara, R., Carrasquillo, M. M., Rademakers, R., & Dickson, D. W. (2014) · Acta Neuropathologica · doi:10.1007/s00401-014-1302-2 · Cited by 145 · cited 4×
“Many studies have demonstrated that LATE-NC is associated with additive cognitive impairment for a given amount of other pathologic changes [4, 16, 17, 72, 103, 111, 127].”
InfluentialSelf-citationIncidence and extent of TDP-43 accumulation in aging human brain
Uchino, A., Takao, M., Hatsuta, H., Sumikura, H., Nakano, Y., Nogami, A., Saito, Y., Arai, T., Nishiyama, K., & Murayama, S. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0215-1 · Cited by 144 · cited 4×
“Similar to other age-related neurodegenerative disease processes, it is not possible to confidently predict clinical implications of LATE-NC in a given individual, especially if there are multiple concurrent pathologies [24, 98, 108, 109, 112, 143, 146].”
InfluentialSelf-citationClinical and Neuropathological Characteristics of Hippocampal Sclerosis: A Community-Based Study
Leverenz, J. B., Agustin, C. M., Tsuang, D., Peskind, E. R., Edland, S. D., Nochlin, D., DiGiacomo, L., Bowen, J. D., McCormick, W. C., Teri, L., et al. (2002) · Archives of Neurology · doi:10.1001/archneur.59.7.1099 · Cited by 144 · cited 1×
“Age-related TDP-43 pathology and associated clinical features have been described by many investigators over past decades [6, 14, 28, 30, 31, 46, 49, 59, 66, 70, 72, 85, 103, 106, 117, 125, 137, 145, 146, 148, 155, 158, 161], but a consensus nomenclature was lacking until recently.”
Self-citationThe Amygdala as a Locus of Pathologic Misfolding in Neurodegenerative Diseases
Nelson, P. T., Abner, E. L., Patel, E., Anderson, S., Wilcock, D. M., Kryscio, R. J., Van Eldik, L. J., Jicha, G. A., Gal, Z., Nelson, R. S., et al. (2018) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlx099 · Cited by 142 · cited 1×
“A recent study focusing on cases with minimal or incipient LATE-NC described cases without NCI, but with short, non-branching TDP-43 immunoreactive structures that frequently localized around corpora amylacea, and/or in aging-related tau astrogliopathy (ARTAG) pathology [29, 37, 110, 128].”
Self-citationTemporal lobar predominance of TDP-43 neuronal cytoplasmic inclusions in Alzheimer disease
Hu, W. T., Josephs, K. A., Knopman, D. S., Boeve, B. F., Dickson, D. W., Petersen, R. C., & Parisi, J. E. (2008) · Acta Neuropathologica · doi:10.1007/s00401-008-0400-4 · Cited by 134 · cited 1×
“Age-related TDP-43 pathology and associated clinical features have been described by many investigators over past decades [6, 14, 28, 30, 31, 46, 49, 59, 66, 70, 72, 85, 103, 106, 117, 125, 137, 145, 146, 148, 155, 158, 161], but a consensus nomenclature was lacking until recently.”
Self-citationThal, D. R., Tredici, K. D., Ludolph, A. C., Hoozemans, J. J. M., Rozemüller, A. J. M., Braak, H., & Knippschild, U. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0871-6 · Cited by 134 · cited 1×
“A potential pitfall for the assessment of LATE-NC is the fact that some phospho-TDP-43 antibodies also detect granulovacuolar degeneration (GVD) [51, 69, 76, 139, 151]—this staining is not considered to represent LATE-NC.”
Self-citationTDP-43 pathology and memory impairment in elders without pathologic diagnoses of AD or FTLD
Nag, S., Yu, L., Wilson, R. S., Chen, E.-Y., Bennett, D. A., & Schneider, J. A. (2017) · Neurology · doi:10.1212/wnl.0000000000003610 · Cited by 130
Self-citationEvaluation of subcortical pathology and clinical correlations in FTLD-U subtypes
Josephs, K. A., Stroh, A., Dugger, B., & Dickson, D. W. (2009) · Acta Neuropathologica · doi:10.1007/s00401-009-0547-7 · Cited by 126 · cited 1×
“In addition, each FTLD-TDP subtype has a fairly distinct pattern of limbic and subcortical involvement that is helpful in their classification [65, 91].”
Self-citationReappraisal of TDP-43 pathology in FTLD-U subtypes
Mackenzie, I. R., & Neumann, M. (2017) · Acta Neuropathologica · doi:10.1007/s00401-017-1716-8 · Cited by 119 · cited 2×
“…of TDP-43 pathology in the cerebral neocortex allow for recognition of at least five subtypes of FTLD-TDP, each with relatively specific clinical and genetic correlations and increasingly recognized molecular differences in the nature of the TDP-43 aggregates [84, 90, 92, 119, 121, 124].”
Self-citationKlein, H., Trumpff, C., Yang, H., Lee, A., Picard, M. A., Bennett, D. A., & Jager, P. L. D. (2021) · Molecular Neurodegeneration · doi:10.1186/s13024-021-00495-8 · Cited by 117 · cited 1×
“This terminology has been adopted widely [16, 25, 48, 50–52, 57, 74, 81, 95, 100, 132, 135, 138, 153].”
Self-citationPallidonigral TDP-43 pathology in Perry syndrome
Wider, C., Dickson, D. W., Stoessl, A. J., Tsuboi, Y., Chapon, F., Gutmann, L., Lechevalier, B., Calne, D. B., Personett, D. A., Hulihan, M., et al. (2009) · Parkinsonism & Related Disorders · doi:10.1016/j.parkreldis.2008.07.005 · Cited by 115 · cited 1×
“For example, TDP-43 pathology is often seen in corticobasal degeneration, Perry syndrome, Alexander disease, and the Parkinsonism–dementia complex diseases of Guam and Kii [43, 75, 148, 152, 156].”
Self-citationTan, R. H., Kril, J. J., Fatima, M., McGeachie, A., McCann, H., Shepherd, C., Forrest, S. L., Affleck, A., Kwok, J. B. J., Hodges, J. R., et al. (2015) · Brain · doi:10.1093/brain/awv220 · Cited by 112
Self-citationTomé, S. O., Vandenberghe, R. R., Ospitalieri, S., Schoor, E. V., Tousseyn, T., Otto, M., Arnim, C. A. F. V., & Thal, D. R. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-00934-5 · Cited by 112 · cited 3×
“Similar to other age-related neurodegenerative disease processes, it is not possible to confidently predict clinical implications of LATE-NC in a given individual, especially if there are multiple concurrent pathologies [24, 98, 108, 109, 112, 143, 146].”
Self-citationHippocampal Sclerosis Contributes to Dementia in the Elderly
Corey-Bloom, J., Sabbagh, M. N., Bondi, M. W., Hansen, L., Alford, M. F., Masliah, E., & Thal, L. J. (1997) · Neurology · doi:10.1212/wnl.48.1.154 · Cited by 110 · cited 1×
“Age-related TDP-43 pathology and associated clinical features have been described by many investigators over past decades [6, 14, 28, 30, 31, 46, 49, 59, 66, 70, 72, 85, 103, 106, 117, 125, 137, 145, 146, 148, 155, 158, 161], but a consensus nomenclature was lacking until recently.”
Geser, F., Robinson, J. L., Malunda, J. A., Xie, S. X., Clark, C. M., Kwong, L. K., Moberg, P. J., Moore, E. M., Van Deerlin, V. M., Lee, V. M.-Y., et al. (2010) · Archives of Neurology · doi:10.1001/archneurol.2010.254 · Cited by 108 · cited 1×
“In LATE-NC, TDP-43 proteinopathy is often detected in cellular compartments outside of the neuronal cell body [11, 29, 39, 116].”
Josephs, K. A., Murray, M. E., Tosakulwong, N., Weigand, S. D., Serie, A. M., Perkerson, R. B., Matchett, B. J., Jack, C. R., Knopman, D. S., Petersen, R. C., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-018-1951-7 · Cited by 106 · cited 3×
“Certain parameters and features (e.g., comorbid Lewy body disease) have been associated with differing patterns of LATE-NC [29, 62].”
Self-citationKadokura, A., Yamazaki, T., Lemere, C. A., Takatama, M., & Okamoto, K. (2009) · Neuropathology · doi:10.1111/j.1440-1789.2009.01017.x · Cited by 105 · cited 1×
“Age-related TDP-43 pathology and associated clinical features have been described by many investigators over past decades [6, 14, 28, 30, 31, 46, 49, 59, 66, 70, 72, 85, 103, 106, 117, 125, 137, 145, 146, 148, 155, 158, 161], but a consensus nomenclature was lacking until recently.”
Zarow, C., Sitzer, T. E., & Chui, H. C. (2008) · Current Neurology and Neuroscience Reports · doi:10.1007/s11910-008-0057-3 · Cited by 104 · cited 1×
“These factors increase the likelihood of poor inter-rater agreement on the neuropathologic diagnosis of HS, and help explain the differing frequencies of HS reported in various autopsy series [34, 38, 73, 86, 88, 102, 118, 144, 159].”
Genotype–phenotype links in frontotemporal lobar degeneration
Mossevelde, S. V., Engelborghs, S., van der Zee, J., & Broeckhoven, C. V. (2018) · Nature Reviews Neurology · doi:10.1038/s41582-018-0009-8 · Cited by 104
Neumann, M., Lee, E. B., & Mackenzie, I. R. (2021) · Advances in Experimental Medicine and Biology · doi:10.1007/978-3-030-51140-1_13 · Cited by 103 · cited 1×
“…of TDP-43 pathology in the cerebral neocortex allow for recognition of at least five subtypes of FTLD-TDP, each with relatively specific clinical and genetic correlations and increasingly recognized molecular differences in the nature of the TDP-43 aggregates [84, 90, 92, 119, 121, 124].”
Self-citationHippocampal sclerosis dementia differs from hippocampal sclerosis in frontal lobe degeneration
Amador-Ortiz, C., Ahmed, Z., Zehr, C., & Dickson, D. W. (2007) · Acta Neuropathologica · doi:10.1007/s00401-006-0183-4 · Cited by 100 · cited 2×
“Age-related TDP-43 pathology and associated clinical features have been described by many investigators over past decades [6, 14, 28, 30, 31, 46, 49, 59, 66, 70, 72, 85, 103, 106, 117, 125, 137, 145, 146, 148, 155, 158, 161], but a consensus nomenclature was lacking until recently.”
Self-citationArnold, S. J., Dugger, B. N., & Beach, T. G. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1110-0 · Cited by 100 · cited 1×
“In LATE-NC, TDP-43 proteinopathy is often detected in cellular compartments outside of the neuronal cell body [11, 29, 39, 116].”
Self-citationPao, W. C., Dickson, D. W., Crook, J. E., Finch, N. A., Rademakers, R., & Graff-Radford, N. R. (2011) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e31820f8f50 · Cited by 98
Self-citationLatimer, C. S., Burke, B. T., Liachko, N. F., Currey, H. N., Kilgore, M. D., Gibbons, L. E., Henriksen, J., Darvas, M., Domoto-Reilly, K., Jayadev, S., et al. (2019) · Acta Neuropathologica Communications · doi:10.1186/s40478-019-0743-1 · Cited by 97 · cited 1×
“This terminology has been adopted widely [16, 25, 48, 50–52, 57, 74, 81, 95, 100, 132, 135, 138, 153].”
Self-citationTau and TDP-43 proteinopathies: kindred pathologic cascades and genetic pleiotropy
Chornenkyy, Y., Fardo, D. W., & Nelson, P. T. (2019) · Laboratory Investigation · doi:10.1038/s41374-019-0196-y · Cited by 93
Self-citationThe TMEM106B locus and TDP-43 pathology in older persons without FTLD
Yu, L., De Jager, P. L., Yang, J., Trojanowski, J. Q., Bennett, D. A., & Schneider, J. A. (2015) · Neurology · doi:10.1212/wnl.0000000000001313 · Cited by 91 · cited 1×
“A genetic risk factor for LATE-NC is TMEM106B [33].”
Self-citationHippocampal sclerosis in Lewy body disease is a TDP-43 proteinopathy similar to FTLD-TDP Type A
Aoki, N., Murray, M. E., Ogaki, K., Fujioka, S., Rutherford, N. J., Rademakers, R., Ross, O. A., & Dickson, D. W. (2015) · Acta Neuropathologica · doi:10.1007/s00401-014-1358-z · Cited by 89 · cited 2×
“It has been recognized for over a decade that TDP-43 pathology is often comorbid with ADNC, Lewy body pathology, or both [8, 10, 46, 66, 67].”
Self-citationPrevalence, laterality, and comorbidity of hippocampal sclerosis in an autopsy sample
Zarow, C., Weiner, M. W., Ellis, W. G., & Chui, H. C. (2012) · Brain and Behavior · doi:10.1002/brb3.66 · Cited by 88 · cited 2×
“Age-related TDP-43 pathology and associated clinical features have been described by many investigators over past decades [6, 14, 28, 30, 31, 46, 49, 59, 66, 70, 72, 85, 103, 106, 117, 125, 137, 145, 146, 148, 155, 158, 161], but a consensus nomenclature was lacking until recently.”
Johnson, V. E., Stewart, W., Trojanowski, J. Q., & Smith, D. H. (2011) · Acta Neuropathologica · doi:10.1007/s00401-011-0909-9 · Cited by 87 · cited 1×
“For persons with a clinical history of brain trauma—traumatic brain injury (TBI) and/or chronic traumatic encephalopathy (CTE)–TDP-43 pathologic changes may be seen, but not necessarily related to LATE-NC [3, 60, 96, 97, 126].”
Pathology of clinical and preclinical Alzheimer’s disease
Thal, D. R., Arnim, C. A. F. V., Griffin, W. S. T., Yamaguchi, H., Mrak, R. E., Attems, J., & Upadhaya, A. R. (2013) · European Archives of Psychiatry and Clinical Neuroscience · doi:10.1007/s00406-013-0449-5 · Cited by 85 · cited 1×
“For more data and discussion related to immunostaining of GVD, see Refs [51, 69, 76, 77, 141, 151].”
Self-citationHippocampal Sclerosis: Progress Since Sommer
Thom, M. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00201.x · Cited by 85 · cited 1×
“For example, the diagnosis of HS is commonly applied in the context of persons with epilepsy, where the pathogenesis is very different (and lacks TDP-43 proteinopathy) in comparison to LATE-NC [118, 136, 142].”
Astrocytic TDP-43 Pathology in Alexander Disease
Walker, A. K., Daniels, C. M. L., Goldman, J. E., Trojanowski, J. Q., Lee, V. M.-Y., & Messing, A. (2014) · The Journal of Neuroscience · doi:10.1523/jneurosci.0248-14.2014 · Cited by 80 · cited 1×
“For example, TDP-43 pathology is often seen in corticobasal degeneration, Perry syndrome, Alexander disease, and the Parkinsonism–dementia complex diseases of Guam and Kii [43, 75, 148, 152, 156].”
Katsumata, Y., Fardo, D. W., Kukull, W. A., & Nelson, P. T. (2018) · Acta Neuropathologica Communications · doi:10.1186/s40478-018-0641-y · Cited by 79 · cited 1×
“In an informal survey of U.S. Alzheimer’s Disease Research Centers, approximately 2/3 rd of the neuropathologists depended on antibodies against the phosphorylated Ser409/Ser410 TDP-43 epitope [71].”
Self-citationLimbic-predominant age-related TDP-43 encephalopathy differs from frontotemporal lobar degeneration
Robinson, J. L., Porta, S., Garrett, F. G., Zhang, P., Xie, S. X., Suh, E. R., Deerlin, V. M. V., Abner, E. L., Jicha, G. A., Barber, J. M., et al. (2020) · Brain · doi:10.1093/brain/awaa219 · Cited by 78
Self-citationGrothe, M. J., Moscoso, A., Silva‐Rodríguez, J., Lange, C., Nho, K. T., Saykin, A. J., Nelson, P. T., Schöll, M., Buchert, R., Teipel, S. J., et al. (2022) · Alzheimer s & Dementia · doi:10.1002/alz.12763 · Cited by 75 · cited 1×
“In recently published studies from five separate autopsy series [29, 41, 80, 109, 143], a small subset of cases from each cohort was reported with TDP-43 pathology in the hippocampal formation, but not in the amygdala.”
Self-citationTDP-43 immunoreactivity in anoxic, ischemic and neoplastic lesions of the central nervous system
Lee, E. B., Lee, V. M. ‐., Trojanowski, J. Q., & Neumann, M. (2007) · Acta Neuropathologica · doi:10.1007/s00401-007-0331-5 · Cited by 71
Self-citationUnique Hard Scleral Lens Post-LASIK Ectasia Fitting
Mahadevan, R., Jagadeesh, D., Rajan, R., & Arumugam, A. O. (2014) · Optometry and Vision Science · doi:10.1097/opx.0000000000000170 · Cited by 69
Josephs, K. A., Mackenzie, I., Frosch, M. P., Bigio, E. H., Neumann, M., Arai, T., Dugger, B. N., Ghetti, B., Grossman, M., Hasegawa, M., et al. (2019) · Brain · doi:10.1093/brain/awz224 · Cited by 66 · cited 1×
“However, diagnostic ambiguities and criticisms of the staging scheme have emerged [22, 61, 115].”
Self-citationDugan, A. J., Nelson, P. T., Katsumata, Y., Shade, L. M. P., Boehme, K. L., Teylan, M., Cykowski, M. D., Mukherjee, S., Kauwe, J. S. K., Hohman, T. J., et al. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01250-2 · Cited by 66 · cited 2×
“These factors increase the likelihood of poor inter-rater agreement on the neuropathologic diagnosis of HS, and help explain the differing frequencies of HS reported in various autopsy series [34, 38, 73, 86, 88, 102, 118, 144, 159].”
Self-citationMackenzie, I. R., & Neumann, M. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02070-4 · Cited by 64 · cited 1×
“In addition, each FTLD-TDP subtype has a fairly distinct pattern of limbic and subcortical involvement that is helpful in their classification [65, 91].”
Self-citationUemura, M. T., Robinson, J. L., Cousins, K. A. Q., Tropea, T. F., Kargilis, D., McBride, J. D., Suh, E. R., Xie, S. X., Xu, Y., Porta, S., et al. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02383-3 · Cited by 62 · cited 1×
“However, these pathologic features also are commonly seen—even when quite severe—in the absence of each other [51, 52, 88, 113, 147, 153, 154], so they are at least partly independent.”
Self-citationLin, W.-L., Castanedes-Casey, M., & Dickson, D. W. (2009) · Journal of Neuropathology and Experimental Neurology · doi:10.1097/nen.0b013e3181baacec · Cited by 61
Self-citationKadokura, A., Yamazaki, T., Kakuda, S., Makioka, K., Lemere, C. A., Fujita, Y., Takatama, M., & Okamoto, K. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.06.024 · Cited by 60 · cited 2×
“For more data and discussion related to immunostaining of GVD, see Refs [51, 69, 76, 77, 141, 151].”
Phosphorylated TDP-43 Staging of Primary Age-Related Tauopathy
Zhang, X., Sun, B., Wang, X., Lu, H. J., Shao, F., Rozemüller, A. J. M., Liang, H., Liu, C., Chen, J., Huang, M., et al. (2018) · Neuroscience Bulletin · doi:10.1007/s12264-018-0300-0 · Cited by 60
TDP-43: From Alzheimer’s Disease to Limbic-Predominant Age-Related TDP-43 Encephalopathy
Huang, W., Zhou, Y., Tu, L., Ba, Z., Huang, J., Huang, N., & Luo, Y. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00026 · Cited by 60 · cited 1×
“This terminology has been adopted widely [16, 25, 48, 50–52, 57, 74, 81, 95, 100, 132, 135, 138, 153].”
Challenges and Considerations Related to Studying Dementia in Blacks/African Americans
Ighodaro, E. T., Nelson, P. T., Kukull, W. A., Schmitt, F. A., Abner, E. L., Caban-Holt, A., Bardach, S. H., Hord, D. C., Glover, C. M., Jicha, G. A., et al. (2017) · Journal of Alzheimer's Disease · doi:10.3233/jad-170242 · Cited by 55 · cited 1×
“Observations in more diverse communities are critical, since socioeconomic, cultural, and/or ancestral aspects may influence clinical–pathological correlation [55, 109, 123, 146].”
Self-citationHippocampal sclerosis: a common pathological feature of dementia in very old humans
Jellinger, K. A. (1994) · Acta Neuropathologica · doi:10.1007/bf00296500 · Cited by 55 · cited 1×
“Age-related TDP-43 pathology and associated clinical features have been described by many investigators over past decades [6, 14, 28, 30, 31, 46, 49, 59, 66, 70, 72, 85, 103, 106, 117, 125, 137, 145, 146, 148, 155, 158, 161], but a consensus nomenclature was lacking until recently.”
Self-citationAgrawal, S., Yu, L., Nag, S., Arfanakis, K., Barnes, L. L., Bennett, D. A., & Schneider, J. A. (2021) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01260-0 · Cited by 52 · cited 1×
“Many studies have demonstrated that LATE-NC is associated with additive cognitive impairment for a given amount of other pathologic changes [4, 16, 17, 72, 103, 111, 127].”
Self-citationGlial TDP‐43 and TDP‐43 induced glial pathology, focus on neurodegenerative proteinopathy syndromes
Prater, K. E., Latimer, C. S., & Jayadev, S. (2021) · Glia · doi:10.1002/glia.24096 · Cited by 51 · cited 2×
“Additional pressing research is needed to define and stratify risk factors and interactions with other diseases, including various neurodegenerative and neurovascular disorders (see, for example, Refs [15, 37, 128]).”
Self-citationThe Delayed Neuropathological Consequences of Traumatic Brain Injury in a Community-Based Sample
Postupna, N., Rose, S. E., Gibbons, L. E., Coleman, N. M., Hellstern, L. L., Ritchie, K., Wilson, A. M., Cudaback, E., Li, X., Melief, E. J., et al. (2021) · Frontiers in Neurology · doi:10.3389/fneur.2021.624696 · Cited by 50 · cited 1×
“For persons with a clinical history of brain trauma—traumatic brain injury (TBI) and/or chronic traumatic encephalopathy (CTE)–TDP-43 pathologic changes may be seen, but not necessarily related to LATE-NC [3, 60, 96, 97, 126].”
Self-citationGauthreaux, K. M., Teylan, M., Katsumata, Y., Mock, C., Culhane, J. E., Chen, Y., Chan, K. C. G., Fardo, D. W., Dugan, A. J., Cykowski, M. D., et al. (2022) · Neurology · doi:10.1212/wnl.0000000000200001 · Cited by 50 · cited 1×
“Based on current knowledge, our recommendations are as follows: • TDP-43 pathology in LATE-NC has histomorphologic features that may be similar to FTLD-TDP type A or less commonly type B [8, 114, 131, 149].”
Self-citationTDP-43 Pathology in the Population: Prevalence and Associations with Dementia and Age
Keage, H. A. D., Cohort, O. B. O. T. C. C. O. 7., Hunter, S., Matthews, F. E., Ince, P. G., Hodges, J., Hokkanen, S. R. K., Highley, J. R., Dening, T., & Brayne, C. (2014) · Journal of Alzheimer's Disease · doi:10.3233/jad-132351 · Cited by 49 · cited 3×
“Many studies have demonstrated that LATE-NC is associated with additive cognitive impairment for a given amount of other pathologic changes [4, 16, 17, 72, 103, 111, 127].”
Self-citationCykowski, M. D., Arumanayagam, A. S., Powell, S. Z.-E., Rivera, A. L., Abner, E. L., Román, G. C., Masdeu, J. C., & Nelson, P. T. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02416-5 · Cited by 48 · cited 7×
“Certain parameters and features (e.g., comorbid Lewy body disease) have been associated with differing patterns of LATE-NC [29, 62].”
InfluentialSelf-citationHippocampal sclerosis, hippocampal neuron loss patterns and TDP‐43 in the aged population
Hokkanen, S. R. K., Hunter, S., Polvikoski, T. M., Keage, H. A. D., Minett, T., Matthews, F. E., Brayne, C., & MRC CFAS and CC75C Study Group (2018) · Brain Pathology · doi:10.1111/bpa.12556 · Cited by 47 · cited 2×
“Prior studies of HS-related histomorphology [45, 56, 160], and the recent work by Hokkanen et al. [47], provided methodologies to study HS pathologic features systematically.”
Self-citationMontine, T. J., Corrada, M. M., Kawas, C., Bukhari, S. A., White, L. R., Tian, L., & Cholerton, B. (2022) · Neurology · doi:10.1212/wnl.0000000000200832 · Cited by 47 · cited 1×
“This terminology has been adopted widely [16, 25, 48, 50–52, 57, 74, 81, 95, 100, 132, 135, 138, 153].”
Self-citationAgrawal, S., Leurgans, S. E., James, B. D., Barnes, L. L., Mehta, R. I., Dams-O’Connor, K., Mez, J., Bennett, D. A. A., & Schneider, J. A. (2022) · JAMA Network Open · doi:10.1001/jamanetworkopen.2022.9311 · Cited by 47
Self-citationGoossens, J., Vanmechelen, E., Trojanowski, J. Q., Lee, V. M., Van Broeckhoven, C., van der Zee, J., & Engelborghs, S. (2015) · Acta Neuropathologica Communications · doi:10.1186/s40478-015-0195-1 · Cited by 43 · cited 2×
“The antibody used for pathologic diagnosis and associated protocols may affect the ability to detect TDP-43 inclusions [40, 53, 79].”
LATE-NC aggravates GVD-mediated necroptosis in Alzheimer’s disease
Koper, M. J., Tomé, S. O., Gawor, K., Belet, A., Schoor, E. V., Schaeverbeke, J. M., Vandenberghe, R. R., Vandenbulcke, M., Ghebremedhin, E., Otto, M., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01432-6 · Cited by 42
Self-citationNeumann, M., Frick, P., Paron, F., Kosten, J., Buratti, E., & Mackenzie, I. R. (2020) · Acta Neuropathologica · doi:10.1007/s00401-020-02207-w · Cited by 42 · cited 2×
“…of TDP-43 pathology in the cerebral neocortex allow for recognition of at least five subtypes of FTLD-TDP, each with relatively specific clinical and genetic correlations and increasingly recognized molecular differences in the nature of the TDP-43 aggregates [84, 90, 92, 119, 121, 124].”
Self-citationNascimento, C., Di Lorenzo Alho, A. T., Bazan Conceição Amaral, C., Leite, R. E. P., Nitrini, R., Jacob‐Filho, W., Pasqualucci, C. A., Hokkanen, S. R. K., Hunter, S., Keage, H., et al. (2018) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12430 · Cited by 41 · cited 1×
“Similar to other age-related neurodegenerative disease processes, it is not possible to confidently predict clinical implications of LATE-NC in a given individual, especially if there are multiple concurrent pathologies [24, 98, 108, 109, 112, 143, 146].”
Self-citationNovel monoclonal antibodies to normal and pathologically altered human TDP-43 proteins
Kwong, L. K., Irwin, D. J., Walker, A. K., Xu, Y., Riddle, D. M., Trojanowski, J. Q., & Lee, V. M. ‐. (2014) · Acta Neuropathologica Communications · doi:10.1186/2051-5960-2-33 · Cited by 41 · cited 2×
“The antibody used for pathologic diagnosis and associated protocols may affect the ability to detect TDP-43 inclusions [40, 53, 79].”
Hokkanen, S. R. K., Kero, M., Kaivola, K., Hunter, S., Keage, H. A. D., Kiviharju, A., Raunio, A., Tienari, P. J., Paetau, A. E., Matthews, F. E., et al. (2019) · Brain Pathology · doi:10.1111/bpa.12773 · Cited by 39 · cited 1×
“This terminology has been adopted widely [16, 25, 48, 50–52, 57, 74, 81, 95, 100, 132, 135, 138, 153].”
Self-citationHarrison, W. T., Lusk, J. B., Liu, B., Ervin, J. F., Johnson, K. G., Green, C. L., & Wang, S. J. (2021) · Acta Neuropathologica · doi:10.1007/s00401-021-02360-w · Cited by 39 · cited 1×
“Clinical–pathological studies demonstrated that LATE-NC is associated with cognitive impairment (often with amnestic features), independent of other disease processes [17, 36, 42, 51, 58, 62, 68, 72, 88, 103, 104, 111, 130, 132, 135].”
Self-citationUnderlying genetic variation in familial frontotemporal dementia: sequencing of 198 patients
Mol, M. O., van Rooij, J., Wong, T. H., Melhem, S., Verkerk, A. J. M. H., Kievit, A. J. A., van Minkelen, R., Rademakers, R., Pottier, C. P., Kaat, L. D., et al. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.07.014 · Cited by 38
Alafuzoff, I. I., Pikkarainen, M., Neumann, M., Arzberger, T., Al‐Sarraj, S., Bódi, I., Bogdanović, N., Bugiani, O., Ferrer, I., Gelpí, E., et al. (2014) · Journal of Neural Transmission · doi:10.1007/s00702-014-1304-1 · Cited by 38 · cited 1×
“Nevertheless, potential pitfalls in the FTLD-TDP subtyping have been discussed due to the presence of mixed subtypes (usually FTLD-TDP types A + B), and overall low inter-rater agreement in separating FTLD-TDP types A and B [5, 9, 90].”
Self-citationLimbic-predominant age-related TDP-43 encephalopathy in Black and White decedents
Nag, S., Barnes, L. L., Yu, L., Wilson, R. S., Bennett, D. A., & Schneider, J. A. (2020) · Neurology · doi:10.1212/wnl.0000000000010602 · Cited by 38 · cited 2×
“(Some recent scholarship has evaluated LATE-NC in cohorts other than Whites [104, 109, 123, 146].)”
Self-citationMotor neuron TDP-43 proteinopathy in progressive supranuclear palsy and corticobasal degeneration
Riku, Y., Iwasaki, Y., Ishigaki, S., Akagi, A., Hasegawa, M., Nishioka, K., Li, Y., Riku, M., Ikeuchi, T., Fujioka, Y., et al. (2022) · Brain · doi:10.1093/brain/awac091 · Cited by 38
Self-citationHippocampal Sclerosis of Aging Can Be Segmental: Two Cases and Review of the Literature
Ighodaro, E. T., Jicha, G. A., Schmitt, F. A., Neltner, J. H., Abner, E. L., Kryscio, R. J., Smith, C. D., Duplessis, T., Anderson, S., Patel, E., et al. (2015) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0000000000000204 · Cited by 37 · cited 1×
“In hippocampi affected by severe HS, pyramidal cell dropout is extensive, and hippocampal atrophy can be extreme [6]; however, in some individuals with LATE-NC, cell loss is segmental (neuronal loss in some portions of the hippocampus and/or subiculum, but not others) [54].”
Self-citationTDP ‐43 Proteinopathy Presenting with Typical Symptoms of Parkinson's Disease
Yamashita, R., Beck, G., Yonenobu, Y., Inoue, K., Mitsutake, A., Ishiura, H., Hasegawa, M., Murayama, S., & Mochizuki, H. (2022) · Movement Disorders · doi:10.1002/mds.29048 · Cited by 37
Self-citationNascimento, C., Suemoto, C. K., Rodriguez, R. D., Alho, A. T. D. L., Leite, R. P., Farfel, J. M., Pasqualucci, C. A. G., Jacob‐Filho, W., & Grinberg, L. T. (2016) · Brain Pathology · doi:10.1111/bpa.12296 · Cited by 36 · cited 4×
“Similar to other age-related neurodegenerative disease processes, it is not possible to confidently predict clinical implications of LATE-NC in a given individual, especially if there are multiple concurrent pathologies [24, 98, 108, 109, 112, 143, 146].”
InfluentialSelf-citationHippocampal Sclerosis in the Oldest Old: A Finnish Population-Based Study
Kero, M., Raunio, A., Polvikoski, T. M., Tienari, P. J., Paetau, A. E., & Myllykangas, L. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-171068 · Cited by 36 · cited 1×
“These factors increase the likelihood of poor inter-rater agreement on the neuropathologic diagnosis of HS, and help explain the differing frequencies of HS reported in various autopsy series [34, 38, 73, 86, 88, 102, 118, 144, 159].”
Self-citationProgressive amnestic dementia, hippocampal sclerosis, and mutation in C9ORF72
Murray, M. E., Bieniek, K. F., Banks Greenberg, M., DeJesus-Hernandez, M., Rutherford, N. J., van Blitterswijk, M., Niemantsverdriet, E., Ash, P. E., Gendron, T. F., Kouri, N., et al. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1161-2 · Cited by 35 · cited 1×
“These factors increase the likelihood of poor inter-rater agreement on the neuropathologic diagnosis of HS, and help explain the differing frequencies of HS reported in various autopsy series [34, 38, 73, 86, 88, 102, 118, 144, 159].”
Self-citationNelson, P. T., Gal, Z. T., Wang, W., Niedowicz, D. M., Artiushin, S., Wycoff, S., Wei, A. L., Jicha, G. A., & Fardo, D. W. (2019) · Neurobiology of Disease · doi:10.1016/j.nbd.2019.01.013 · Cited by 35 · cited 1×
“In LATE-NC, TDP-43 proteinopathy is often detected in cellular compartments outside of the neuronal cell body [11, 29, 39, 116].”
Self-citationAssociation of glial tau pathology and LATE-NC in the ageing brain
Forrest, S. L., Wagner, S., Kim, A., & Kovács, G. G. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2022.07.010 · Cited by 35 · cited 2×
“Additional pressing research is needed to define and stratify risk factors and interactions with other diseases, including various neurodegenerative and neurovascular disorders (see, for example, Refs [15, 37, 128]).”
Węgiel, J., Flory, M. J., Kuchna, I., Nowicki, K., Wegiel, J., Ma, S. Y., Zhong, N., Wierzba‐Bobrowicz, T., de Leon, M., Lai, F., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-021-01300-9 · Cited by 35 · cited 1×
“However, these pathologic features also are commonly seen—even when quite severe—in the absence of each other [51, 52, 88, 113, 147, 153, 154], so they are at least partly independent.”
Schoor, E. V., Koper, M. J., Ospitalieri, S., Dedeene, L., Tomé, S. O., Vandenberghe, R. R., Brenner, D., Otto, M., Weishaupt, J. H., Ludolph, A. C., et al. (2020) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12668 · Cited by 34 · cited 2×
“For more data and discussion related to immunostaining of GVD, see Refs [51, 69, 76, 77, 141, 151].”
Self-citationSignificance and limitation of the pathological classification of TDP ‐43 proteinopathy
Arai, T. (2014) · Neuropathology · doi:10.1111/neup.12138 · Cited by 32
Hippocampal sclerosis, TDP‐43, and the duration of the symptoms of dementia of AD patients
López, O. L., Kofler, J., Chang, Y., Berman, S., Becker, J. T., Sweet, R. A., Nadkarni, N. K., Patira, R., Kamboh, M. I., Cohen, A. D., et al. (2020) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.51135 · Cited by 30 · cited 3×
“These factors increase the likelihood of poor inter-rater agreement on the neuropathologic diagnosis of HS, and help explain the differing frequencies of HS reported in various autopsy series [34, 38, 73, 86, 88, 102, 118, 144, 159].”
Relative neuron loss in hippocampal sclerosis of aging and Alzheimer's disease
Ihara, R., Vincent, B. D., Baxter, M. R., Franklin, E. E., Hassenstab, J. J., Xiong, C., Morris, J. C., & Cairns, N. J. (2018) · Annals of Neurology · doi:10.1002/ana.25344 · Cited by 29 · cited 1×
“Prior studies of HS-related histomorphology [45, 56, 160], and the recent work by Hokkanen et al. [47], provided methodologies to study HS pathologic features systematically.”
Wang, S. J., Guo, Y., Ervin, J. F., Lusk, J. B., & Luo, S. (2022) · Acta Neuropathologica · doi:10.1007/s00401-022-02432-5 · Cited by 28 · cited 2×
“This terminology has been adopted widely [16, 25, 48, 50–52, 57, 74, 81, 95, 100, 132, 135, 138, 153].”
Self-citationTDP ‐43 Pathology Exacerbates Cognitive Decline in Primary Age‐Related Tauopathy
Smirnov, D. S., Salmon, D. P., Galasko, D. R., Edland, S. D., Pizzo, D. P., Goodwill, V., & Hiniker, A. O. (2022) · Annals of Neurology · doi:10.1002/ana.26438 · Cited by 27 · cited 2×
“This terminology has been adopted widely [16, 25, 48, 50–52, 57, 74, 81, 95, 100, 132, 135, 138, 153].”
Lack of association of the apoE4 allele with hippocampal sclerosis dementia
Troncoso, J. C., Kawas, C. H., Chang, C. K., Folstein, M. F., & Hedreen, J. C. (1996) · Neuroscience Letters · doi:10.1016/0304-3940(96)12331-4 · Cited by 26
Self-citationPatterns of Mixed Pathologies in Down Syndrome
Ichimata, S., Yoshida, K., Visanji, N. P., Lang, A. E., Nishida, N., & Kovacs, G. G. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-215675 · Cited by 25 · cited 2×
“This terminology has been adopted widely [16, 25, 48, 50–52, 57, 74, 81, 95, 100, 132, 135, 138, 153].”
Self-citationTazwar, M., Evia, A. M., Tamhane, A. A., Ridwan, A. R., Leurgans, S. E., Bennett, D. A., Schneider, J. A., & Arfanakis, K. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2022.05.009 · Cited by 24 · cited 1×
“This terminology has been adopted widely [16, 25, 48, 50–52, 57, 74, 81, 95, 100, 132, 135, 138, 153].”
Self-citationNeuropathology studies of dementia in US persons other than non-Hispanic whites
Nguyen, M.-L., Huie, E. Z., Whitmer, R. A., George, K. M., & Dugger, B. N. (2022) · Free Neuropathology · doi:10.17879/freeneuropathology-2022-3795 · Cited by 24
Self-citationTDP-43 Neuropathologic Associations in the Nun Study and the Honolulu-Asia Aging Study
Flanagan, M. E., Cholerton, B., Latimer, C. S., Hemmy, L. S., Edland, S. D., Montine, K. S., White, L. R., & Montine, T. J. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180162 · Cited by 22 · cited 1×
“Clinical–pathological studies demonstrated that LATE-NC is associated with cognitive impairment (often with amnestic features), independent of other disease processes [17, 36, 42, 51, 58, 62, 68, 72, 88, 103, 104, 111, 130, 132, 135].”
Self-citationMcAleese, K. E., Walker, L., Erskine, D., Johnson, M. A., Koss, D. J., Thomas, A. J., & Attems, J. (2020) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12664 · Cited by 20 · cited 1×
“This terminology has been adopted widely [16, 25, 48, 50–52, 57, 74, 81, 95, 100, 132, 135, 138, 153].”
Self-citationRisk factors of hippocampal sclerosis in the oldest old
Trieu, T., Sajjadi, S. A., Kawas, C. H., Nelson, P. T., & Corrada, M. M. (2018) · Neurology · doi:10.1212/wnl.0000000000006455 · Cited by 19 · cited 1×
“These factors increase the likelihood of poor inter-rater agreement on the neuropathologic diagnosis of HS, and help explain the differing frequencies of HS reported in various autopsy series [34, 38, 73, 86, 88, 102, 118, 144, 159].”
Self-citationNelson, P. T., Dickson, D. W., Trojanowski, J. Q., Jack, C. R., Boyle, P. A., Arfanakis, K., Rademakers, R., Alafuzoff, I. I., Attems, J., Brayne, C., et al. (2019) · Brain · doi:10.1093/brain/awz226 · Cited by 18 · cited 1×
“However, diagnostic ambiguities and criticisms of the staging scheme have emerged [22, 61, 115].”
Self-citationThe TMEM106B locus and TDP-43 pathology in older persons without FTLD
Dickson, D. W., Rademakers, R., & Nicholson, A. M. (2015) · Neurology · doi:10.1212/01.wnl.0000472918.79256.a9 · Cited by 17
Self-citationOld age amyotrophic lateral sclerosis and limbic TDP‐43 pathology
Murakami, A., Koga, S., Sekiya, H., Oskarsson, B., Boylan, K., Petrucelli, L., Josephs, K. A., & Dickson, D. W. (2022) · Brain Pathology · doi:10.1111/bpa.13100 · Cited by 17 · cited 1×
“…regarding age at disease onset, or age at death, were observed between different stages of TDP-43 pathology, a recent study found medial temporal lobe TDP-43 pathology in 8/8 older ALS cases (> 75 years of age at death) [101], suggesting that in ALS, there may be pathology overlapping with LATE-NC.”
Self-citationTDP-43-associated atrophy in brains with and without frontotemporal lobar degeneration
Buciuc, M., Martin, P. R., Tosakulwong, N., Murray, M. E., Petrucelli, L., Senjem, M. L., Spychalla, A. J., Knopman, D. S., Boeve, B. F., Petersen, R. C., et al. (2022) · NeuroImage Clinical · doi:10.1016/j.nicl.2022.102954 · Cited by 17
Self-citationSaveri, P., Magri, S., Maderna, E., et al. (2022) · European Journal of Neurology · doi:10.1111/ene.15326 · Cited by 16
Buciuc, M., Whitwell, J. L., Baker, M., Rademakers, R., Dickson, D. W., & Josephs, K. A. (2021) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12727 · Cited by 16 · cited 2×
“More work is needed to delineate aspects of biological overlap and differences between LATE-NC and FTLD-TDP, particularly for FTLD-TDP in advanced old age [22].”
Self-citationHunter, S., Hokkanen, S. R. K., Keage, H. A. D., Fleming, J., Minett, T., Polvikoski, T. M., Allinson, K. S. J., & Brayne, C. (2020) · Journal of Alzheimer s Disease · doi:10.3233/jad-191093 · Cited by 15 · cited 4×
“For more data and discussion related to immunostaining of GVD, see Refs [51, 69, 76, 77, 141, 151].”
InfluentialSelf-citationRevisiting the utility of TDP-43 immunoreactive (TDP-43-ir) pathology to classify FTLD-TDP subtypes
Nishihira, Y., Gefen, T. D., Mao, Q., Appin, C., Kohler, M., Walker, J. M., Rademakers, R., RADEMAKER, A. W., Rogalski, E. J., Weıntraub, S., et al. (2019) · Acta Neuropathologica · doi:10.1007/s00401-019-02024-w · Cited by 14 · cited 1×
“…of TDP-43 pathology in the cerebral neocortex allow for recognition of at least five subtypes of FTLD-TDP, each with relatively specific clinical and genetic correlations and increasingly recognized molecular differences in the nature of the TDP-43 aggregates [84, 90, 92, 119, 121, 124].”
Self-citationMyositis with sarcoplasmic inclusions in Nakajo–Nishimura syndrome: a genetic inflammatory myopathy
Ayaki, T., Murata, K., Kanazawa, N., Uruha, A., Ohmura, K., Sugie, K., Kasagi, S., Li, F., Mori, M., Nakajima, R., et al. (2020) · Neuropathology and Applied Neurobiology · doi:10.1111/nan.12614 · Cited by 14 · cited 1×
“TDP-43 pathology is now known to occur in more than 20 different conditions spanning neurodegenerative, developmental, trauma-related, myopathic, and even neoplastic disease categories [2, 13, .”
Integrated neurodegenerative disease autopsy diagnosis
Lee, E. B. (2018) · Acta Neuropathologica · doi:10.1007/s00401-018-1827-x · Cited by 13 · cited 1×
“It may be helpful for practicing neuropathologists to provide inter-pretive summaries, but we emphasize that this should be a separate comment with a focus on interpretation of findings in nontechnical language [82].”
Self-citationMelikyan, Z. A., Corrada, M. M., Leiby, A. C., Sajjadi, S. A., Bukhari, S. A., Montine, T. J., & Kawas, C. H. (2022) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2022.03.009 · Cited by 13 · cited 1×
“Similar to other age-related neurodegenerative disease processes, it is not possible to confidently predict clinical implications of LATE-NC in a given individual, especially if there are multiple concurrent pathologies [24, 98, 108, 109, 112, 143, 146].”
Self-citationClinical Aspects of Hippocampal Sclerosis
Leverenz, J. B., & Lipton, A. M. (2008) · Handbook of clinical neurology · doi:10.1016/s0072-9752(07)01252-3 · Cited by 12 · cited 1×
“These factors increase the likelihood of poor inter-rater agreement on the neuropathologic diagnosis of HS, and help explain the differing frequencies of HS reported in various autopsy series [34, 38, 73, 86, 88, 102, 118, 144, 159].”
Self-citationCancer and Vascular Comorbidity Effects on Dementia Risk and Neuropathology in the Oldest-Old
Lachner, C., Day, G. S., Camsari, G. B., Kouri, N., Ertekin‐Taner, N., Boeve, B. F., Labuzan, S. A., Lucas, J. A., Thompson, E. A., Siddiqui, H., et al. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220440 · Cited by 8 · cited 2×
“Another recent study confirmed that there are cases with TDP-43 + processes but lacking TDP-43 + NCIs [80].”
Self-citationJamerlan, A., & An, S. S. A. (2020) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2020.06.020 · Cited by 8 · cited 1×
“This terminology has been adopted widely [16, 25, 48, 50–52, 57, 74, 81, 95, 100, 132, 135, 138, 153].”
A novel missense HNRNPA1 variant in the PY-NLS domain in a patient with late-onset distal myopathy
Chompoopong, P., Milone, M., Niu, Z., et al. (2022) · Neuromuscular Disorders · doi:10.1016/j.nmd.2022.03.009 · Cited by 7
Koyano, S., Yagishita, S., Tada, M., Doi, H., Uchihara, T., & Tanaka, F. (2022) · Journal of Neuropathology & Experimental Neurology · doi:10.1093/jnen/nlac032 · Cited by 5
An Autopsy-Proven Case of Limbic-Predominant Age-Related TDP-43 Encephalopathy
Cho, S. H., Choi, S., Kim, B. C., Song, W.-Y., Kim, H.-S., & Lee, K. (2020) · Yonsei Medical Journal · doi:10.3349/ymj.2020.61.8.731 · Cited by 3 · cited 1×
“This terminology has been adopted widely [16, 25, 48, 50–52, 57, 74, 81, 95, 100, 132, 135, 138, 153].”
Cited by
McKee, A. C., Stein, T. D., Huber, B. R., Crary, J. F., Bieniek, K., Dickson, D., Alvarez, V. E., Cherry, J. D., Farrell, K., Butler, M., et al. (2023) · Acta Neuropathologica · doi:10.1007/s00401-023-02540-w · Cited by 244
Self-citationHuang, Z., Merrihew, G. E., Larson, E. B., Park, J., Plubell, D., Fox, E. J., Montine, K. S., Latimer, C. S., Dirk Keene, C., Zou, J. Y., et al. (2023) · Nature Communications · doi:10.1038/s41467-023-38376-x · Cited by 37
“Antibodies to phospho-TDP-43 (anti-pTPD-43, S409/410, Millipore, cat#MABN14, dilution 1:300) and phospho-alpha-synuclein (Anti-Alpha-synuclein, ps129, Abcam, cat#ab51253, dilution 1:1000) also were used in speci fi ed regions 47,49 .”
Self-citationFazeli, E., Child, D. D., Bucks, S. A., Stovarsky, M., Edwards, G., Rose, S. E., Yu, C.-E., Latimer, C., Kitago, Y., Bird, T., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-023-02670-1 · Cited by 29
Self-citationJury-Garfe, N., Redding-Ochoa, J., You, Y., Martínez, P., Karahan, H., Chimal-Juárez, E., Johnson, T. S., Zhang, J., Resnick, S., Kim, J., et al. (2024) · Acta Neuropathologica · doi:10.1007/s00401-024-02775-1 · Cited by 31
Self-citationPlasma ApoE proteotyping for ApoE ε4 stratification in the anti-amyloid therapies era
Coraglia, F., Cecchetti, G., Rugarli, G., Spinelli, E. G., Ghirelli, A., Pisano, S., Canu, E., Filippi, M., & Agosta, F. (2026) · Alzheimer's Research & Therapy · doi:10.1186/s13195-026-02089-2 · Cited by 1
Metadata
- Authors
- Nelson, P. T., Lee, E. B., Cykowski, M. D., Alafuzoff, I., Arfanakis, K., Attems, J., Brayne, C., Corrada, M. M., Dugger, B. N., Flanagan, M. E., Ghetti, B., Grinberg, L. T., Grossman, M., Grothe, M. J., Halliday, G. M., Hasegawa, M., Hokkanen, S. R. K., Hunter, S., Jellinger, K., Kawas, C. H., Keene, C. D., Kouri, N., Kovacs, G. G., Leverenz, J. B., Latimer, C. S., Mackenzie, I. R., Mao, Q., McAleese, K. E., Merrick, R., Montine, T. J., Murray, M. E., Myllykangas, L., Nag, S., Neltner, J. H., Newell, K. L., Rissman, R. A., Saito, Y., Sajjadi, S. A., Schwetye, K. E., Teich, A. F., Thal, D. R., Tomé, S. O., Troncoso, J. C., Wang, S.-H. J., White, C. L., Wisniewski, T., Yang, H.-S., Schneider, J. A., Dickson, D. W., & Neumann, M.
- Venue
- Acta Neuropathologica
- Published
- 2022-12-13
- Volume
- 145
- Issue
- 2
- Pages
- 159-173
- ISSN
- 0001-6322 (ISSN-L)
- 1432-0533
- OpenAlex
- W4311237378
- Cited by
- 176
- References
- 156
- FWCI
- 16.22
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.